Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.21 USD
0.00 (0.00%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $2.21 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 121 - 140 ( 270 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
February and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RG-101 Could Be Lifted in Q1 2018 and We Look to Additional Pipeline Progress in 2017; Reiterate
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 30
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 16
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
January and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
R-D Day Highlights Expanding Clinical Pipeline; Reiterate OUTPERFORM and $13 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
December and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
November and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q3 Update: Well Capitalized to Weather Minor Delays in Lead Programs; Reiterate OUTPERFORM but Reducing PT to $13
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 17
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
October and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of September 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
September and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q2 Financial Results; We Project Cash Runway Covers Potentially Transformational Catalysts; Reiterate OUTPERFORM and $15 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
August and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of August 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
July and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L